US4675187A
(en)
|
1983-05-16 |
1987-06-23 |
Bristol-Myers Company |
BBM-1675, a new antibiotic complex
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
GB9021679D0
(en)
|
1990-10-05 |
1990-11-21 |
Gorman Scott David |
Antibody preparation
|
ES2181673T3
(es)
|
1991-05-01 |
2003-03-01 |
Jackson H M Found Military Med |
Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
US5874082A
(en)
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
ATE255906T1
(de)
|
1993-10-01 |
2003-12-15 |
Immunex Corp |
Antikörper gegen cd40
|
AU680102B2
(en)
|
1993-12-23 |
1997-07-17 |
Immunex Corporation |
Method of preventing or treating disease characterized by neoplastic cells expressing CD40
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
CN1110557C
(zh)
|
1994-05-06 |
2003-06-04 |
古斯达威罗斯研究所 |
Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
|
WO1996032471A2
(en)
|
1995-04-10 |
1996-10-17 |
Universite De Sherbrooke |
Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
DK0885002T3
(da)
|
1996-03-04 |
2011-08-22 |
Penn State Res Found |
Materialer og fremgangsmåder til forøgelse af cellulær internalisering
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
EP0914452A2
(en)
|
1996-06-17 |
1999-05-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
|
WO1997049424A1
(en)
|
1996-06-25 |
1997-12-31 |
The Trustees Of The University Of Pennsylvania |
Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
|
NL1003648C2
(nl)
|
1996-07-19 |
1998-01-21 |
Carino Cornelis Sunderman |
Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
|
ES2236832T3
(es)
|
1997-01-16 |
2005-07-16 |
Massachusetts Institute Of Technology |
Preparacion de particulas para inhalacion.
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
US7259247B1
(en)
|
1997-09-23 |
2007-08-21 |
Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes |
Anti-human T-cell costimulating polypeptide monoclonal antibodies
|
PT1032662E
(pt)
|
1997-11-07 |
2006-07-31 |
Trillium Therapeutics Inc |
Metodos e composicoes para imunomodulacao.
|
US6051228A
(en)
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
EP1068357B2
(en)
|
1998-03-30 |
2014-12-10 |
NorthWest Biotherapeutics, Inc. |
Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
|
GB9809839D0
(en)
|
1998-05-09 |
1998-07-08 |
Glaxo Group Ltd |
Antibody
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
WO1999061057A2
(en)
|
1998-05-23 |
1999-12-02 |
Tanox, Inc. |
Molecules targeting cd40 and tumor cells
|
AU747231B2
(en)
|
1998-06-24 |
2002-05-09 |
Alkermes, Inc. |
Large porous particles emitted from an inhaler
|
MXPA01000481A
(es)
|
1998-07-16 |
2002-11-29 |
Hyseq Inc |
Metodos y materiales relacionados con polipeptidos tipo cd39 novedosos.
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
AU1224200A
(en)
|
1998-10-23 |
2000-05-15 |
Agnes Vignery |
Methods for modulating cell fusion
|
NZ512553A
(en)
|
1998-12-23 |
2004-02-27 |
Pfizer |
Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4)
|
US6245332B1
(en)
|
1999-01-15 |
2001-06-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of systemic memory T cell trafficking
|
US6488930B1
(en)
|
1999-01-15 |
2002-12-03 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR4 antibodies and methods of use therefor
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
EP1048299A1
(en)
|
1999-04-28 |
2000-11-02 |
Faculteit der Geneeskunde van de Vrije Universiteit |
Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
KR100942863B1
(ko)
|
1999-08-24 |
2010-02-17 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
AU6934600A
(en)
|
1999-08-27 |
2001-03-26 |
Board Of Regents, The University Of Texas System |
Cd40 ligand and cd40 agonist compositions and methods of use
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
GB9927757D0
(en)
|
1999-11-25 |
2000-01-26 |
Kennedy Rheumatology Inst |
Treatment of autoimmune diseases
|
EP1244707A1
(de)
|
1999-11-30 |
2002-10-02 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Antikörper gegen signal-regulator-proteine
|
US20030049251A1
(en)
|
1999-12-08 |
2003-03-13 |
Barbas Carlos F. |
Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
|
DE10001372A1
(de)
|
2000-01-14 |
2001-08-02 |
Deutsches Krebsforsch |
Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
CA2401491C
(en)
|
2000-03-03 |
2011-07-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Ccr4-binding antibody and diagnostic and therapeutic uses thereof
|
AU2001253496A1
(en)
|
2000-04-14 |
2001-10-30 |
Millennium Pharmaceuticals, Inc. |
Treating graft rejection with cxcr3 inhibitors
|
WO2001083755A2
(en)
|
2000-04-28 |
2001-11-08 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
WO2002011762A2
(en)
|
2000-08-03 |
2002-02-14 |
Gorczynski Reginald M |
Methods and compositions for modulating tumor growth
|
CA2420226C
(en)
|
2000-08-18 |
2012-08-07 |
The Regents Of The University Of California |
Methods for treating demyelinating diseases
|
US7052676B2
(en)
|
2000-09-26 |
2006-05-30 |
The Regents Of The University Of Michigan |
Methods for inhibition of HIV replication using a small molecule inhibitor
|
ES2357051T3
(es)
|
2000-10-02 |
2011-04-15 |
Novartis Vaccines And Diagnostics, Inc. |
Anticuerpos humanos anti-cd40.
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
EP1341902A2
(en)
|
2000-12-08 |
2003-09-10 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US20040198661A1
(en)
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
US7282556B2
(en)
|
2001-05-15 |
2007-10-16 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
|
WO2003006058A1
(en)
|
2001-07-12 |
2003-01-23 |
Wyeth |
Cd25+ differential markers and uses thereof
|
AU2002316674B2
(en)
|
2001-07-12 |
2007-09-13 |
The Regents Of The University Of California |
CXCL10 treatment of secondary tissue degeneration
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
CA2458627C
(en)
|
2001-08-31 |
2013-09-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Human cdr-grafted antibody and antibody fragment thereof
|
WO2003029296A1
(en)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Human anti-cd40 antibodies
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
EP4091631A1
(en)
|
2002-01-30 |
2022-11-23 |
The Brigham and Women's Hospital, Inc. |
A tim-3 binding molecule for use in the treatment of a disease
|
AU2003209059A1
(en)
|
2002-02-08 |
2003-09-02 |
Genetastix Corporation |
Human monoclonal antibodies against membrane proteins
|
DE10161767T1
(de)
|
2002-07-03 |
2018-06-07 |
Honjo Tasuku |
Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
|
EP1539237A4
(en)
|
2002-07-30 |
2006-05-24 |
Bristol Myers Squibb Co |
HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
|
ES2559763T3
(es)
|
2002-09-10 |
2016-02-15 |
Affimed Gmbh |
Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
|
EP1549678A4
(en)
|
2002-09-30 |
2006-01-18 |
Pfizer Prod Inc |
HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
|
WO2004045525A2
(en)
|
2002-11-15 |
2004-06-03 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
|
AU2003291549A1
(en)
|
2002-11-15 |
2004-06-15 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
|
WO2004052397A1
(en)
|
2002-12-05 |
2004-06-24 |
Protein Design Labs, Inc. |
Methods of treatment of ulcerative colitis with anti-cd3 antibodies
|
US20060121030A1
(en)
|
2002-12-16 |
2006-06-08 |
Herbert Schwarz |
Use of cd 137 antagonists for the treatment of tumors
|
US20050002939A1
(en)
|
2002-12-23 |
2005-01-06 |
Albert Zlotnik |
Tumor killing/tumor regression using CXCR4 antagonists
|
US7521051B2
(en)
|
2002-12-23 |
2009-04-21 |
Medimmune Limited |
Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
|
MXPA05006978A
(es)
|
2002-12-27 |
2005-08-16 |
Schering Corp |
Metodos para inducir y mantener la tolerancia inmune.
|
CA2517287C
(en)
|
2003-02-28 |
2022-12-13 |
The Johns Hopkins University |
Regulation of t cells by lag-3 (cd223)
|
WO2004082714A1
(en)
|
2003-03-17 |
2004-09-30 |
The Regents Of The University Of California |
Methods for treating ocular inflammation by neutralizing cxcl10 activity
|
EP1462114A1
(en)
|
2003-03-28 |
2004-09-29 |
Universiteit Utrecht Holding B.V. |
Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
|
WO2004101511A2
(en)
|
2003-05-09 |
2004-11-25 |
Protein Design Labs, Inc |
Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
|
JP3936673B2
(ja)
|
2003-06-02 |
2007-06-27 |
国立大学法人群馬大学 |
Cd47部分ペプチドと抗shps−1モノクロナール抗体
|
JP2006526414A
(ja)
|
2003-06-02 |
2006-11-24 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
脱免疫化抗cd3抗体
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
PL207804B1
(pl)
|
2003-07-29 |
2011-02-28 |
Htl Strefa Społka Z Ograniczoną Odpowiedzialnością |
Przyrząd do nakłuwania
|
CA2534711A1
(en)
|
2003-08-01 |
2005-02-10 |
Medarex, Inc. |
Combination therapies for multiple sclerosis
|
WO2005023201A2
(en)
|
2003-09-09 |
2005-03-17 |
Medarex, Inc. |
Methods for treating rheumatoid arthritis
|
JPWO2005035582A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
Ccr4に特異的に結合する抗体組成物
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
PL2149585T3
(pl)
|
2003-11-04 |
2014-01-31 |
Novartis Vaccines & Diagnostics Inc |
Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40
|
PT1682177E
(pt)
|
2003-11-04 |
2010-11-29 |
Xoma Technology Lt |
Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
|
ES2346978T3
(es)
|
2003-11-04 |
2010-10-22 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
|
ATE516819T1
(de)
|
2003-11-04 |
2011-08-15 |
Novartis Vaccines & Diagnostic |
Verfahren zur behandlung von b-zell-bedingtem krebs
|
CA2544852A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
|
EP1702625B1
(en)
|
2003-12-04 |
2010-11-03 |
Kyowa Hakko Kirin Co., Ltd. |
Medicine containing genetically modified antibody against chemokine receptor ccr4
|
WO2005060457A2
(en)
|
2003-12-04 |
2005-07-07 |
Pdl Biopharma, Inc. |
Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
|
CN102838675B
(zh)
|
2003-12-10 |
2014-07-30 |
梅达雷克斯有限责任公司 |
Ip-10抗体及其用途
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
WO2005063981A1
(ja)
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗cd40抗体の変異体
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
US20090208486A1
(en)
|
2004-03-09 |
2009-08-20 |
Makoto Taketo |
Pharmaceutical composition comprising cxcr3 inhibitor
|
CA2562764A1
(en)
|
2004-04-23 |
2005-11-03 |
Richard Kroczek |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
BRPI0510317A
(pt)
|
2004-04-27 |
2007-10-16 |
Novartis Vaccines & Diagnostic |
anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
US20090252741A1
(en)
|
2004-09-08 |
2009-10-08 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
WO2006039819A1
(en)
|
2004-10-15 |
2006-04-20 |
St. Michael's Hospital |
Markers of lung injury
|
WO2006050172A2
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
JP2008518902A
(ja)
|
2004-11-04 |
2008-06-05 |
ファイザー・プロダクツ・インク |
乳癌のためのctla4抗体とアロマターゼ阻害剤の併用治療
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
US8329178B2
(en)
|
2005-02-18 |
2012-12-11 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against CXCR4 and methods of use thereof
|
WO2006096488A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising human igg2 antibody and chelating agent
|
US20090074787A1
(en)
|
2005-03-23 |
2009-03-19 |
Pfizer, Inc., Pfizer Products, Inc. |
Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
|
AU2006227879A1
(en)
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
JP4177436B2
(ja)
|
2005-04-26 |
2008-11-05 |
株式会社ステリック再生医科学研究所 |
肝細胞複製促進剤およびインスリン抵抗性改善剤
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
JP5027804B2
(ja)
|
2005-05-26 |
2012-09-19 |
シアトル ジェネティクス,インコーポレーテッド |
ヒト化抗cd40抗体およびその使用方法
|
CA2617539A1
(en)
|
2005-07-01 |
2007-01-11 |
Washington University In St. Louis |
Phosphospecific chemokine receptor antibodies
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
BRPI0612408A2
(pt)
|
2005-07-07 |
2010-11-03 |
Pfizer |
terapia para tratamento de cáncer em combinação com anticorpo anti-ctla-4 e oligodesoxinucleotìdeo sintético contendo o motivo cpg
|
EP1945260B1
(en)
|
2005-11-01 |
2012-10-24 |
Novartis AG |
Uses of anti-cd40 antibodies
|
KR101395005B1
(ko)
|
2005-11-01 |
2014-05-21 |
조마 테크놀로지 리미티드 |
항cd40 항체의 용도
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
RU2520088C2
(ru)
|
2006-01-12 |
2014-06-20 |
Алексион Фармасьютикалз, Инк. |
Антитела к ох-2/сd200 и их применение
|
EP1981969A4
(en)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
EP2001509A1
(en)
|
2006-04-03 |
2008-12-17 |
Medizinische Hochschule Hannover |
Pharmaceuticals for influencing the reaction of the human immune system
|
MEP39508A
(en)
|
2006-04-21 |
2011-02-10 |
Novartis Ag |
Antagonist anti-cd40 antibody pharmaceutical compositions
|
CN104357469B
(zh)
|
2006-05-03 |
2018-10-26 |
科罗拉多州立大学董事会 |
Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
SI2066351T1
(sl)
|
2006-10-02 |
2016-02-29 |
E.R. Squibb & Sons, L.L.C. |
Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
|
US8178100B2
(en)
|
2006-10-13 |
2012-05-15 |
Seoul National University Industry Foundation |
Antibodies to IP-10 for treating bone diseases with bone destruction
|
JP2010013355A
(ja)
|
2006-10-19 |
2010-01-21 |
Stelic Institute Of Regenerative Medicine |
心筋障害抑制剤
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
EA200970477A1
(ru)
|
2006-11-15 |
2009-12-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к btla и способы применения
|
WO2008073316A2
(en)
|
2006-12-07 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Identification and isolation of acute myeloid leukemia stem cells
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
NZ704295A
(en)
*
|
2006-12-27 |
2016-06-24 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
AU2008207898B2
(en)
|
2007-01-23 |
2012-05-03 |
Xencor, Inc |
Optimized CD40 antibodies and methods of using the same
|
JP2010518873A
(ja)
|
2007-02-27 |
2010-06-03 |
ジェネンテック, インコーポレイテッド |
アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
|
AU2008219570B2
(en)
|
2007-02-28 |
2013-08-22 |
Novimmune Sa |
Human anti-IP-10 antibodies and uses thereof
|
FR2915102B1
(fr)
|
2007-04-23 |
2014-05-16 |
Pf Medicament |
Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
SI2170959T1
(sl)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
Protitelesa proti receptorjem pd-1 za humano programirano smrt
|
WO2009009547A2
(en)
|
2007-07-09 |
2009-01-15 |
Qualcomm Incorporated |
Methods for sending small packets in a peer-to-peer (p2p) network
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
EP3124046B1
(en)
|
2007-07-12 |
2019-12-25 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
AU2008279619B2
(en)
|
2007-07-25 |
2013-11-14 |
Alexion Pharmaceuticals, Inc. |
Antibodies to CD200 and uses thereof in inhibiting immune responses
|
EP2581441A1
(en)
|
2007-08-09 |
2013-04-17 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
AU2008310263B2
(en)
|
2007-10-11 |
2014-09-11 |
University Health Network |
Modulation of SIRPALPHA - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
BRPI0820707A2
(pt)
|
2007-11-07 |
2015-06-16 |
Genentech Inc |
Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
|
MX2010005099A
(es)
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
AU2009206506B2
(en)
|
2008-01-23 |
2013-01-10 |
Xencor, Inc. |
Optimized CD40 antibodies and methods of using the same
|
ES2848323T3
(es)
|
2008-01-31 |
2021-08-06 |
Inst Nat Sante Rech Med |
Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
AR070316A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
NZ587830A
(en)
|
2008-03-14 |
2012-08-31 |
Transgene Sa |
Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
EP2252318A4
(en)
|
2008-03-20 |
2012-04-18 |
Carolus Therapeutics Inc |
PROCESS FOR TREATMENT OF IGNITION
|
WO2009120186A1
(en)
|
2008-03-24 |
2009-10-01 |
Carolus Therapeutics, Inc. |
Methods and compositions for treating atherosclerosis and related conditions
|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
JP2011519866A
(ja)
|
2008-05-01 |
2011-07-14 |
ベス イスラエル デアコネス メディカル センター |
前立腺癌免疫療法のための方法および組成物
|
CA2724409A1
(en)
|
2008-05-14 |
2009-11-19 |
Eli Lilly And Company |
Anti-cxcr4 antibodies
|
CA2724208C
(en)
|
2008-05-16 |
2018-02-06 |
Ablynx Nv |
Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
|
CN102007147B
(zh)
|
2008-06-30 |
2014-11-05 |
协和发酵麒麟株式会社 |
抗cd27抗体
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010024676A1
(en)
|
2008-08-29 |
2010-03-04 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Delivery of a cd40 agonist to a tumor draining lymph node of a subject
|
WO2010029434A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
KR102097887B1
(ko)
|
2008-09-26 |
2020-04-06 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
LT2398498T
(lt)
|
2009-02-17 |
2019-01-10 |
Ucb Biopharma Sprl |
Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
CA2754906C
(en)
|
2009-03-10 |
2021-02-09 |
Baylor Research Institute |
Antigen presenting cell targeted fusion proteins comprising a linker for increased stability
|
CN106432493B
(zh)
|
2009-03-10 |
2020-01-31 |
贝勒研究院 |
抗-cd40抗体及其用途
|
EP3002296B1
(en)
|
2009-03-17 |
2020-04-29 |
Université d'Aix-Marseille |
Btla antibodies and uses thereof
|
AU2010236168B2
(en)
|
2009-04-18 |
2015-08-13 |
Genentech, Inc. |
Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
|
PL2423228T3
(pl)
|
2009-04-20 |
2016-06-30 |
Kyowa Hakko Kirin Co Ltd |
Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
EP3871498A1
(en)
|
2009-07-08 |
2021-09-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3199551A3
(en)
|
2009-07-31 |
2017-10-18 |
E. R. Squibb & Sons, L.L.C. |
Fully human antibodies to btla
|
JP5883384B2
(ja)
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
US20110117113A1
(en)
|
2009-10-09 |
2011-05-19 |
Gerald Beste |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
HUE037159T2
(hu)
|
2009-11-24 |
2018-08-28 |
Medimmune Ltd |
Targetált kötõdõ ágensek B7-H1 ellen
|
DK2949670T3
(da)
|
2009-12-10 |
2019-05-13 |
Hoffmann La Roche |
Antistoffer, der fortrinsvis binder humant ekstracellulært CSF1R-domæne 4 og anvendelse deraf
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
ES2705015T3
(es)
|
2009-12-29 |
2019-03-21 |
Kyowa Hakko Kirin Co Ltd |
Anticuerpo anti-CD27
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
BR112012020101A2
(pt)
|
2010-02-11 |
2018-09-25 |
Alexion Pharma Inc |
método diagnósticos e terapêuticos usando anticorpos anti-cd200.
|
MX336682B
(es)
|
2010-03-05 |
2016-01-27 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humanos y usos de los mismos.
|
EP2542587A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
PT3178851T
(pt)
|
2010-03-31 |
2020-07-17 |
Boehringer Ingelheim Int |
Anticorpos anti-cd40
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
CN103154034B
(zh)
|
2010-04-13 |
2016-06-08 |
塞尔德克斯医疗公司 |
结合人cd27的抗体及其用途
|
NZ603193A
(en)
|
2010-05-04 |
2014-07-25 |
Five Prime Therapeutics Inc |
Antibodies that bind csf1r
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
CN105695415A
(zh)
|
2010-06-17 |
2016-06-22 |
科马布有限公司 |
动物模型及治疗分子
|
WO2011161266A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
JP2013538191A
(ja)
*
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
PE20131403A1
(es)
|
2010-08-23 |
2014-01-10 |
Univ Texas |
Anticuerpos anti-ox40 y metodos de uso de los mismos
|
MY162737A
(en)
|
2010-09-09 |
2017-07-14 |
Pfizer |
4-1bb binding molecules
|
WO2012040207A2
(en)
|
2010-09-20 |
2012-03-29 |
Yale University |
HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
|
EP2621951A1
(en)
|
2010-09-29 |
2013-08-07 |
Université de Liège |
Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
|
EP2632953A1
(en)
|
2010-10-27 |
2013-09-04 |
Pierre Fabre Medicament |
Antibodies for the treatment of hiv
|
TWI619811B
(zh)
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
EP3211001B1
(en)
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
EP2654789B1
(en)
|
2010-12-22 |
2018-05-30 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
ES2734076T3
(es)
|
2011-02-17 |
2019-12-04 |
Kyowa Hakko Kirin Co Ltd |
Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
ES2733646T3
(es)
|
2011-03-11 |
2019-12-02 |
Beth Israel Deaconess Medical Ct Inc |
Anticuerpos anti-CD40 y usos de los mismos
|
ES2612914T3
(es)
|
2011-03-31 |
2017-05-19 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra Icos y usos de los mismos
|
KR102289394B1
(ko)
|
2011-03-31 |
2021-08-13 |
머크 샤프 앤드 돔 코포레이션 |
인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
|
EP3536708A1
(en)
|
2011-04-19 |
2019-09-11 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
KR101734614B1
(ko)
|
2011-04-21 |
2017-05-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd40을 길항하는 항체 폴리펩티드
|
WO2012149356A2
(en)
|
2011-04-29 |
2012-11-01 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
MX2013012284A
(es)
|
2011-04-29 |
2013-11-21 |
Bristol Myers Squibb Co |
Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
|
SI2714733T1
(sl)
|
2011-05-21 |
2019-06-28 |
Macrogenics, Inc. |
CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
|
WO2012173819A2
(en)
|
2011-06-14 |
2012-12-20 |
Mayo Foundation For Medical Education And Research |
Anti-cd3 therapies
|
WO2012174338A2
(en)
|
2011-06-15 |
2012-12-20 |
Glaxosmithkline Llc |
Method of selecting therapeutic indications
|
CA2838478A1
(en)
|
2011-06-16 |
2012-12-20 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
WO2012177788A1
(en)
|
2011-06-20 |
2012-12-27 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
ES2758884T3
(es)
|
2011-06-24 |
2020-05-06 |
Stephen D Gillies |
Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
CA3158257A1
(en)
|
2011-07-11 |
2013-01-17 |
Ichnos Sciences SA |
Antibodies that bind to ox40 and their uses
|
US20140314784A1
(en)
|
2011-07-20 |
2014-10-23 |
Medlmmune Limited |
Anti-cxcr4 antibodies and methods of use
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
AR087363A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ox40 항체 및 이의 사용 방법
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
US20140242095A1
(en)
|
2011-10-19 |
2014-08-28 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
SG11201401639QA
(en)
|
2011-10-21 |
2014-05-29 |
Transgene Sa |
Modulation of macrophage activation
|
SI2776032T1
(sl)
|
2011-11-09 |
2018-12-31 |
Bristol-Myers Squibb Company |
Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
AU2012344260B2
(en)
*
|
2011-11-28 |
2017-09-07 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
JP6242804B2
(ja)
|
2011-12-15 |
2017-12-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトcsf−1rに対する抗体及びその使用
|
GB201203442D0
(en)
*
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
MY175224A
(en)
|
2012-03-15 |
2020-06-16 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods, and uses
|
WO2013158856A2
(en)
|
2012-04-20 |
2013-10-24 |
Emergent Product Development Seattle, Llc |
Cd3 binding polypeptides
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子1受容体(csf1r)を結合させる抗体を用いて状態を治療する方法
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
CN103417967B
(zh)
|
2012-05-15 |
2017-05-10 |
中国医学科学院基础医学研究所 |
Cxcl‑10抑制剂在制备治疗和/或预防肺损伤的药物中的用途
|
CN115093480A
(zh)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
CN104602707A
(zh)
|
2012-06-06 |
2015-05-06 |
昂考梅德药品有限公司 |
调节hippo途径的结合剂及其应用
|
CA2915412A1
(en)
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
EP3786183A3
(en)
|
2012-06-15 |
2021-06-09 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
EP2866830A4
(en)
|
2012-06-27 |
2015-12-09 |
Jyant Technologies |
ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION
|
US20140005352A1
(en)
|
2012-06-29 |
2014-01-02 |
Invista North America S.A R.L. |
Gas scrubber and related processes
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
DE102012013637A1
(de)
|
2012-07-09 |
2014-01-09 |
Iwis Motorsysteme Gmbh & Co. Kg |
Triebstockplanetengetriebe
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
AU2013308635A1
(en)
|
2012-08-31 |
2015-03-12 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトcd40モノクローナル抗体及びその利用
|
WO2014065402A1
(ja)
|
2012-10-26 |
2014-05-01 |
株式会社ペルセウスプロテオミクス |
抗ヒトcd40モノクローナル抗体及びその利用
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
TWI539961B
(zh)
|
2012-11-09 |
2016-07-01 |
轉殖基因公司 |
單核球或其前驅細胞分化之調節
|
BR112015013127A2
(pt)
|
2012-12-04 |
2017-09-26 |
Oncomed Pharm Inc |
imunoterapia com agentes de ligação
|
BR112015014621A2
(pt)
*
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
DK2970473T3
(da)
|
2013-03-14 |
2017-11-27 |
Bristol Myers Squibb Co |
Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
|
ME03796B
(me)
|
2013-03-15 |
2021-04-20 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
US9097712B2
(en)
|
2013-03-15 |
2015-08-04 |
Allied Innovative Systems Llc |
Flow-through cell counting assay
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
WO2014169255A1
(en)
|
2013-04-11 |
2014-10-16 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions of treating autoimmune diseases
|
WO2014170317A1
(en)
|
2013-04-17 |
2014-10-23 |
Morphosys Ag |
Antibodies targeting specifically human cxcr2
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
US9815897B2
(en)
|
2013-05-02 |
2017-11-14 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (PD-1)
|
WO2014189306A1
(ko)
|
2013-05-22 |
2014-11-27 |
메타볼랩(주) |
항 TNF-α/CXCL10 이중 타겟 항체 및 그의 용도
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
CN105683217B
(zh)
|
2013-05-31 |
2019-12-10 |
索伦托治疗有限公司 |
与pd-1结合的抗原结合蛋白
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
AU2014286116A1
(en)
|
2013-07-05 |
2016-02-04 |
Genmab A/S |
Humanized or chimeric CD3 antibodies
|
CN113583128A
(zh)
|
2013-08-01 |
2021-11-02 |
鲁汶大学 |
抗garp蛋白及其用途
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
WO2015016718A1
(en)
|
2013-08-02 |
2015-02-05 |
Bionovion Holding B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
WO2015024042A1
(en)
|
2013-08-22 |
2015-02-26 |
The Council Of The Queensland Institute Of Medical Research |
Immunoreceptor modulation for treating cancer and viral infections
|
WO2015024060A1
(en)
|
2013-08-22 |
2015-02-26 |
The Council Of The Queensland Institute Of Medical Research |
Immunoreceptor modulation for treating cancer and viral infections
|
GB201315486D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
SG11201601763SA
(en)
|
2013-09-20 |
2016-04-28 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
ES2742079T3
(es)
|
2013-11-06 |
2020-02-13 |
Bristol Myers Squibb Co |
Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
|
DK3081576T3
(da)
|
2013-12-12 |
2019-10-21 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
|
RS60443B1
(sr)
|
2013-12-17 |
2020-07-31 |
Genentech Inc |
Anti-cd3 antitela i postupci upotrebe
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
EP3083685A2
(en)
|
2013-12-20 |
2016-10-26 |
Intervet International B.V. |
Canine antibodies with modified ch2-ch3 sequences
|
SI3712174T1
(sl)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Protitelesa in delci proti VISTA
|
RU2016129959A
(ru)
|
2013-12-30 |
2018-02-02 |
Эпимаб Биотерепьютикс Инк. |
Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
|
DK3094351T3
(da)
|
2014-01-15 |
2022-02-21 |
Kadmon Corp Llc |
Immunmodulatoriske midler
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
PL3556775T3
(pl)
|
2014-01-28 |
2022-01-31 |
Bristol-Myers Squibb Company |
Przeciwciała anty-lag-3 w leczeniu nowotworów hematologicznych
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3113796A1
(en)
|
2014-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
US10081680B2
(en)
|
2014-03-11 |
2018-09-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
|
KR20230097209A
(ko)
|
2014-03-12 |
2023-06-30 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
DK3126394T3
(da)
|
2014-03-31 |
2020-01-13 |
Hoffmann La Roche |
Anti-OX40-antistoffer og fremgangsmåder til anvendelse
|
EP3134102B1
(en)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
WO2015169811A2
(en)
|
2014-05-06 |
2015-11-12 |
Medimmune Limited |
Anti-cxc chemokine receptor-2 binding molecules and uses thereof
|
SG10201810108PA
(en)
|
2014-05-13 |
2018-12-28 |
Medimmune Ltd |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
|
JP2017517506A
(ja)
|
2014-05-21 |
2017-06-29 |
ファイザー・インコーポレイテッド |
癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
EP3149042B1
(en)
|
2014-05-29 |
2019-08-28 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
WO2015198312A1
(en)
|
2014-06-24 |
2015-12-30 |
Ccam Therapeutics Ltd. |
Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
AU2015292678B2
(en)
|
2014-07-22 |
2020-10-22 |
Cb Therapeutics, Inc. |
Anti-PD-1 antibodies
|
US10669337B2
(en)
|
2014-07-25 |
2020-06-02 |
Cytomx Therapeutics, Inc. |
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
US10435470B2
(en)
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
UA119783C2
(uk)
|
2014-08-12 |
2019-08-12 |
Аллігатор Біосайенс Аб |
Комбінований препарат з антитілом до cd40
|
AU2015303239A1
(en)
|
2014-08-14 |
2016-12-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibodies activating human CD40 and antibodies against human PD-L1
|
WO2016028810A1
(en)
|
2014-08-18 |
2016-02-25 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
AP2017009765A0
(en)
|
2014-08-19 |
2017-02-28 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
BR112016030670A2
(pt)
*
|
2014-08-29 |
2017-10-31 |
Hoffmann La Roche |
"imunocitoquina"
|
EP3201230B1
(en)
|
2014-09-30 |
2020-12-23 |
Intervet International B.V. |
Pd-l1 antibodies binding canine pd-l1
|
WO2016054638A1
(en)
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
AU2015328273B2
(en)
|
2014-10-06 |
2020-09-17 |
Dana-Farber Cancer Institute, Inc. |
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
|
MX2017004691A
(es)
|
2014-10-10 |
2017-10-02 |
Innate Pharma |
Bloqueo de cd73.
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
AU2015333687B2
(en)
|
2014-10-14 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to PD-L1 and uses thereof
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
AU2015340056A1
(en)
|
2014-10-27 |
2017-05-25 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
KR102011205B1
(ko)
|
2014-11-06 |
2019-08-14 |
에프. 호프만-라 로슈 아게 |
항-tim3 항체 및 사용 방법
|
WO2016073845A1
(en)
|
2014-11-07 |
2016-05-12 |
Igenica Biotherapeutics, Inc. |
Anti-cd39 antibodies and uses thereof
|
GB2537445A
(en)
|
2014-11-10 |
2016-10-19 |
Medimmune Ltd |
Binding molecules specific for CD73 and uses thereof
|
WO2016077397A2
(en)
|
2014-11-11 |
2016-05-19 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
EP3237447B1
(en)
|
2014-12-22 |
2020-12-02 |
Five Prime Therapeutics, Inc. |
Anti-csf1r antibodies for treating pvns
|
ES2881484T3
(es)
|
2014-12-22 |
2021-11-29 |
Pd 1 Acquisition Group Llc |
Anticuerpos anti-PD-1
|
KR102644115B1
(ko)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Tigit에 대한 항체
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
SG10202111844VA
(en)
|
2015-01-09 |
2021-12-30 |
Adalta Ltd |
Cxcr4 binding molecules
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
CN114230667A
(zh)
|
2015-01-23 |
2022-03-25 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
EP3253413A2
(en)
|
2015-02-06 |
2017-12-13 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
WO2016130986A1
(en)
|
2015-02-13 |
2016-08-18 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
EP3259288A1
(en)
|
2015-02-20 |
2017-12-27 |
Innate Pharma |
Cd73 blockade
|
JP2018508509A
(ja)
|
2015-02-22 |
2018-03-29 |
ソレント・セラピューティクス・インコーポレイテッド |
Cd137に結合する抗体医薬
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
CN114907481A
(zh)
|
2015-03-23 |
2022-08-16 |
震动疗法股份有限公司 |
Icos的抗体
|
CN107530429B
(zh)
|
2015-03-30 |
2021-12-07 |
斯特库比股份有限公司 |
特异性针对糖基化的pd-l1的抗体及其使用方法
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
CN107646039B
(zh)
|
2015-04-02 |
2022-04-15 |
埃博灵克斯股份有限公司 |
具有有效抗hiv活性的双特异性cxcr4-cd4多肽
|
PL3283527T3
(pl)
|
2015-04-13 |
2021-06-14 |
Five Prime Therapeutics, Inc. |
Leczenie skojarzone nowotworów
|
WO2016171722A1
(en)
|
2015-04-24 |
2016-10-27 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
WO2016176583A1
(en)
|
2015-04-29 |
2016-11-03 |
Sanford-Burnham Medical Research Institute |
Modulation of immune response using btla agonist antibodies
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
EP3288977B1
(en)
|
2015-05-01 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
US10259882B2
(en)
|
2015-05-07 |
2019-04-16 |
Agenus Inc. |
Anti-OX40 antibodies
|
EP3091032A1
(en)
|
2015-05-08 |
2016-11-09 |
Miltenyi Biotec GmbH |
Humanized antibody or fragment thereof specific for cd3
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ox40に対する抗体およびその使用
|
EP3303395B1
(en)
|
2015-05-29 |
2019-12-11 |
AbbVie Inc. |
Anti-cd40 antibodies and uses thereof
|
CN108025018B
(zh)
|
2015-05-29 |
2021-08-17 |
默沙东公司 |
用于治疗癌症的pd-1拮抗剂和cpg-c型寡核苷酸的组合产品
|
PL3303394T3
(pl)
|
2015-05-29 |
2020-11-16 |
Agenus Inc. |
Przeciwciała anty-ctla-4 i sposoby ich zastosowania
|
BR112017025297A2
(pt)
|
2015-06-03 |
2018-08-14 |
Bristol-Myers Squibb Company |
anticorpos anti-gitr para diagnóstico do câncer
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
EP3307777A4
(en)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
NOVEL ANTI-PD-L1 ANTIBODIES
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
CA2987716A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
JP7350467B2
(ja)
|
2015-06-29 |
2023-09-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
Cd40に対する抗体
|
BR112017028353A2
(pt)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
anticorpos para cd40 com atividade agonista melhorada
|
CN106331470A
(zh)
|
2015-07-03 |
2017-01-11 |
中兴通讯股份有限公司 |
一种拍摄终端和拍摄方法
|
EP3115376B1
(en)
|
2015-07-10 |
2018-09-05 |
Merus N.V. |
Human cd3 binding antibody
|
WO2017009442A1
(en)
|
2015-07-15 |
2017-01-19 |
Genmab A/S |
Humanized or chimeric cd3 antibodies
|
CN114853891A
(zh)
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
LT3328419T
(lt)
|
2015-07-30 |
2021-11-10 |
Macrogenics, Inc. |
Pd-1 surišančios molekulės ir jų panaudojimo būdai
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
CA2994635A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
MA42626A
(fr)
|
2015-08-11 |
2018-06-20 |
Open Monoclonal Tech Inc |
Nouveaux anticorps anti-pd-1
|
CN115925931A
(zh)
|
2015-08-14 |
2023-04-07 |
默沙东公司 |
抗tigit抗体
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
HUE063528T2
(hu)
|
2015-09-01 |
2024-01-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
|
BR112018003186A2
(pt)
|
2015-09-01 |
2018-09-25 |
Agenus Inc. |
anticorpos anti-pd-1 e seus métodos de uso
|
JP7074341B2
(ja)
|
2015-09-02 |
2022-05-24 |
イムテップ エス.アー.エス. |
抗lag-3抗体
|
WO2017037707A1
(en)
|
2015-09-02 |
2017-03-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
WO2017049038A2
(en)
|
2015-09-16 |
2017-03-23 |
Ablexis, Llc |
Anti-cd115 antibodies
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
AU2016325858B2
(en)
|
2015-09-24 |
2022-05-26 |
Daiichi Sankyo Company, Limited |
Anti-GARP antibody
|
CR20180225A
(es)
|
2015-09-25 |
2018-07-09 |
Genentech Inc |
Anticuerpo anti-tigit y métodos de uso
|
RU2722451C1
(ru)
|
2015-09-29 |
2020-06-01 |
Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. |
Pd-1 антитела и их применение.
|
CA2997963A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
US20190048089A1
(en)
|
2015-09-30 |
2019-02-14 |
Janssen Biotech, Inc. |
Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
|
SG10201912943RA
(en)
|
2015-10-02 |
2020-02-27 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
SI3356411T1
(sl)
|
2015-10-02 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Bispecifična protitelesa, specifična za PD1 in TIM3
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
CN114380908B
(zh)
|
2015-10-15 |
2023-03-17 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
CN108697791B
(zh)
|
2015-11-03 |
2022-08-23 |
詹森生物科技公司 |
特异性结合pd-1的抗体及其用途
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
JO3739B1
(ar)
|
2015-11-18 |
2021-01-31 |
Merck Sharp & Dohme |
روابط ctla4
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
EP3383904A4
(en)
|
2015-11-19 |
2019-12-04 |
Zeling Cai |
CTLA-4 ANTIBODIES AND USES THEREOF
|
EP3377533A2
(en)
|
2015-11-19 |
2018-09-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
WO2017089334A1
(en)
|
2015-11-23 |
2017-06-01 |
Innate Pharma |
Cd39 vascular isoform targeting agents
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
AU2019343850A1
(en)
*
|
2018-09-17 |
2020-06-25 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|